The introduction of nicotinamide for a nicotine substitution in e-cigarette and smokeless products represents a substantial regulatory challenge for that FDA. Nicotinamide doesn't have nicotinic receptor agonist activity and is known to act as a sedative at substantial dosages6. The statements m